Fig. 3

Anti-tumor effect of ¹⁷⁷Lu-octreotate on GOT1-bearing nude mice. The relative tumor volume vs. time after last administration is shown for studies 1 and 2. a Evaluation of the anti-tumor effect of the priming treatment schedule used in the biodistribution and dosimetry study (5 + 10 MBq). b Results from groups receiving a smaller priming administration and larger subsequent administration than in the biodistribution and dosimetry study (0.5 + 14.5 and 2.5 + 12.5 MBq, respectively). c Anti-tumor effect in groups receiving a larger priming administration and smaller subsequent administration than in the biodistribution and dosimetry study (10 + 5 MBq) or a larger single administration (30 MBq). Measurements for non-treated animals and animals treated with 15 MBq ¹⁷⁷Lu-octreotate are also shown in a–c for comparison. d Mean animal body weight in therapeutic studies 1 and 2 (note the scale of the y axis). The relative tumor volume reduction was statistically significant in the 2.5 + 12.5 MBq group and 5 + 10 MBq group (study 1 but not study 2) compared with the 15 MBq group (Student’s t test, p < 0.05), shown as the plus symbol at the top of the graph in a and b, respectively. Symbols represent mean relative tumor volumes. Error bars indicate SEM. Black arrow indicates start of treatment